EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Documenti analoghi

• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  di: Pao, William, et al.
  Pubblicazione: (2005)
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  di: Pao, William, et al.
  Pubblicazione: (2005)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  di: Zakowski, Maureen F., et al.
  Pubblicazione: (2009)
• Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman
  di: Kim, Hoon-Kyo, et al.
  Pubblicazione: (2007)
• Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
  di: Politi, Katerina, et al.
  Pubblicazione: (2010)